AR109706A1 - INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g - Google Patents
INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / gInfo
- Publication number
- AR109706A1 AR109706A1 ARP170102631A ARP170102631A AR109706A1 AR 109706 A1 AR109706 A1 AR 109706A1 AR P170102631 A ARP170102631 A AR P170102631A AR P170102631 A ARP170102631 A AR P170102631A AR 109706 A1 AR109706 A1 AR 109706A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phosfatidilinositol
- quinasa
- dual inhibitors
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), caracterizado porque X es C(O) o SO₂; Y es SO₂NHR⁵ o SO₂R⁶; R¹ se selecciona de alquilo C₁₋₄, caracterizado porque dicho alquilo C₁₋₄ es opcionalmente sustituido por ciclopropilo, 0, 1 ó 2 CH₃ y 0, 1, 2 ó 3 F; R² se selecciona de H o CH₃; R³ se selecciona de H o alquilo C₁₋₃; R⁴ se selecciona de alquilo C₁₋₃, caracterizado porque dicho alquilo C₁₋₃ es opcionalmente sustituido por 0 alquilo C₁₋₃; o R³ y R⁴ tomados juntos con el átomo N y X forman un anillo de cicloheteroalquilo con 5, 6 ó 7 elementos que contiene 0 ó 1 heteroátomos adicionales seleccionados de N u O, caracterizado porque dicho anillo de cicloheteroalquilo es sustituido por 0, 1 ó 2 sustituyentes independientemente seleccionados de CH₃, OH, CH₂OH o CH₂CH₂OH; o R³ y R⁴ tomados juntos con el átomo N y X se seleccionan de los restos de fórmula (2) ó (3); R⁵ se selecciona de alquilo C₁₋₃ u (oxetan-3-ilo); R⁶ se selecciona de alquilo C₁₋₃; o una sal del mismo aceptable desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662398006P | 2016-09-22 | 2016-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR109706A1 true AR109706A1 (es) | 2019-01-16 |
Family
ID=59966739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170102631A AR109706A1 (es) | 2016-09-22 | 2017-09-22 | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g |
Country Status (35)
Country | Link |
---|---|
US (2) | US10961236B2 (es) |
EP (1) | EP3515910B1 (es) |
JP (1) | JP6765516B2 (es) |
KR (1) | KR102226098B1 (es) |
CN (1) | CN109715623A (es) |
AR (1) | AR109706A1 (es) |
AU (1) | AU2017331940B2 (es) |
BR (1) | BR112019004719A2 (es) |
CA (1) | CA3036304A1 (es) |
CL (1) | CL2019000707A1 (es) |
CO (1) | CO2019003440A2 (es) |
CR (1) | CR20190200A (es) |
CY (1) | CY1123346T1 (es) |
DK (1) | DK3515910T3 (es) |
DO (1) | DOP2019000073A (es) |
EA (1) | EA036176B1 (es) |
EC (1) | ECSP19027780A (es) |
ES (1) | ES2818583T3 (es) |
HR (1) | HRP20201175T1 (es) |
HU (1) | HUE051634T2 (es) |
IL (1) | IL265298B (es) |
JO (1) | JOP20190052A1 (es) |
LT (1) | LT3515910T (es) |
MA (1) | MA46268B1 (es) |
MX (2) | MX2019003194A (es) |
PE (1) | PE20190909A1 (es) |
PH (1) | PH12019500615A1 (es) |
PL (1) | PL3515910T3 (es) |
PT (1) | PT3515910T (es) |
RS (1) | RS60764B1 (es) |
SI (1) | SI3515910T1 (es) |
SV (1) | SV2019005857A (es) |
TW (1) | TW201813967A (es) |
UA (1) | UA123558C2 (es) |
WO (1) | WO2018055040A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11078204B2 (en) | 2018-11-13 | 2021-08-03 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
WO2022017371A1 (zh) * | 2020-07-21 | 2022-01-27 | 中国医药研究开发中心有限公司 | 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途 |
WO2022023456A1 (en) | 2020-07-29 | 2022-02-03 | Astrazeneca Ab | Pharmaceutical compositions comprising nano embedded microparticles and methods of use |
CN116813608B (zh) * | 2023-06-08 | 2024-03-22 | 英矽智能科技(上海)有限公司 | 噻唑类化合物及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4405726B2 (ja) * | 2000-12-21 | 2010-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | Tecファミリーチロシンキナーゼのチアゾリルインヒビター |
GB0305152D0 (en) * | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
GB0320197D0 (en) * | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
AU2006258101A1 (en) * | 2005-06-09 | 2006-12-21 | Merck Sharp & Dohme Corp. | Inhibitors of checkpoint kinases |
US7928140B2 (en) * | 2007-08-02 | 2011-04-19 | Amgen Inc. | Benzothiazole PI3 kinase modulators for cancer treatment |
UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
AR088218A1 (es) | 2011-07-19 | 2014-05-21 | Infinity Pharmaceuticals Inc | Compuestos heterociclicos utiles como inhibidores de pi3k |
WO2013012915A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2846431A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
TW201446767A (zh) | 2013-02-15 | 2014-12-16 | Almirall Sa | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 |
WO2015001491A1 (en) | 2013-07-02 | 2015-01-08 | Rhizen Pharmaceuticals Sa | Pi3k protein kinase inhibitors, particularly delta and/or gamma inhibitors |
UY35675A (es) | 2013-07-24 | 2015-02-27 | Novartis Ag | Derivados sustituidos de quinazolin-4-ona |
CA2951370A1 (en) | 2014-06-27 | 2015-12-30 | Rhizen Pharmaceuticals Sa | Substituted chromene derivatives as selective dual inhibitors of pi3 delta and gamma protein kinases |
-
2017
- 2017-06-16 JO JOP/2019/0052A patent/JOP20190052A1/ar unknown
- 2017-09-21 MX MX2019003194A patent/MX2019003194A/es unknown
- 2017-09-21 MA MA46268A patent/MA46268B1/fr unknown
- 2017-09-21 PE PE2019000702A patent/PE20190909A1/es unknown
- 2017-09-21 KR KR1020197010973A patent/KR102226098B1/ko active IP Right Grant
- 2017-09-21 JP JP2019515477A patent/JP6765516B2/ja not_active Expired - Fee Related
- 2017-09-21 AU AU2017331940A patent/AU2017331940B2/en not_active Ceased
- 2017-09-21 CN CN201780057289.2A patent/CN109715623A/zh active Pending
- 2017-09-21 PL PL17772381.4T patent/PL3515910T3/pl unknown
- 2017-09-21 SI SI201730357T patent/SI3515910T1/sl unknown
- 2017-09-21 EA EA201990664A patent/EA036176B1/ru not_active IP Right Cessation
- 2017-09-21 LT LTEP17772381.4T patent/LT3515910T/lt unknown
- 2017-09-21 CA CA3036304A patent/CA3036304A1/en not_active Abandoned
- 2017-09-21 TW TW106132359A patent/TW201813967A/zh unknown
- 2017-09-21 BR BR112019004719A patent/BR112019004719A2/pt not_active IP Right Cessation
- 2017-09-21 PT PT177723814T patent/PT3515910T/pt unknown
- 2017-09-21 DK DK17772381.4T patent/DK3515910T3/da active
- 2017-09-21 EP EP17772381.4A patent/EP3515910B1/en active Active
- 2017-09-21 US US16/332,620 patent/US10961236B2/en active Active
- 2017-09-21 ES ES17772381T patent/ES2818583T3/es active Active
- 2017-09-21 RS RS20201077A patent/RS60764B1/sr unknown
- 2017-09-21 WO PCT/EP2017/073916 patent/WO2018055040A1/en unknown
- 2017-09-21 HU HUE17772381A patent/HUE051634T2/hu unknown
- 2017-09-21 CR CR20190200A patent/CR20190200A/es unknown
- 2017-09-21 UA UAA201903648A patent/UA123558C2/uk unknown
- 2017-09-22 AR ARP170102631A patent/AR109706A1/es unknown
-
2019
- 2019-03-11 IL IL265298A patent/IL265298B/en active IP Right Grant
- 2019-03-19 CL CL2019000707A patent/CL2019000707A1/es unknown
- 2019-03-20 MX MX2021004748A patent/MX2021004748A/es unknown
- 2019-03-20 DO DO2019000073A patent/DOP2019000073A/es unknown
- 2019-03-21 PH PH12019500615A patent/PH12019500615A1/en unknown
- 2019-03-22 SV SV2019005857A patent/SV2019005857A/es unknown
- 2019-04-08 CO CONC2019/0003440A patent/CO2019003440A2/es unknown
- 2019-04-17 EC ECSENADI201927780A patent/ECSP19027780A/es unknown
-
2020
- 2020-07-28 HR HRP20201175TT patent/HRP20201175T1/hr unknown
- 2020-09-09 CY CY20201100856T patent/CY1123346T1/el unknown
-
2021
- 2021-02-11 US US17/173,826 patent/US20210246130A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR109706A1 (es) | INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g | |
AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
AR109349A1 (es) | Compuestos y usos | |
AR119761A2 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
AR101367A1 (es) | Pirimidinonas como inhibidores del factor xia | |
AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
CL2020001218A1 (es) | Compuestos útiles para inhibir a cdk7. | |
UY36121A (es) | ?pirazolopiridinas y pirazolopirimidinas?. | |
AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
AR099955A1 (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
AR094553A1 (es) | Formas de oxadiazolpirazina | |
AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
AR111494A1 (es) | Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer | |
AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR095097A1 (es) | Compuestos de fenoxietoxi | |
AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
AR112086A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
AR101591A1 (es) | Compuestos bicíclicos sustituidos | |
AR101696A1 (es) | Compuestos de azetidiniloxifenilpirrolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |